DELCATH SYSTEMS, INC. Logo

DELCATH SYSTEMS, INC.

Interventional oncology company treating liver cancers with targeted chemotherapy.

DCTH | US

Overview

Corporate Details

ISIN(s):
US24661P8077
LEI:
Country:
United States of America
Address:
566 QUEENSBURY AVENUE, 12804 QUEENSBURY

Description

Delcath Systems, Inc. is a commercial-stage interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company develops and commercializes proprietary products for percutaneous hepatic perfusion (PHP), a minimally-invasive procedure designed to administer high-dose chemotherapy directly to the liver while controlling systemic exposure. Its flagship product in the United States is the HEPZATO KIT™ (melphalan/hepatic delivery system), an FDA-approved drug/device combination product for treating adult patients with metastatic uveal melanoma. In Europe, the company markets the CHEMOSAT® Hepatic Delivery System, a medical device for the same procedure.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-25 22:15 English 6.7 KB
2025-11-20 22:45
8-K
English 48.7 KB
2025-11-13 17:53 English 6.6 KB
2025-11-04 15:04
10-Q
English 1.3 MB
2025-11-04 14:02
8-K
English 93.6 KB
2025-10-20 12:01
8-K
English 146.5 KB
2025-10-18 00:05 English 12.4 KB
2025-08-15 22:46
S-8
English 64.8 KB
2025-08-15 22:15
8-K
English 132.4 KB
2025-08-06 15:14
10-Q
English 1.5 MB
2025-08-06 14:03
8-K
English 92.9 KB
2025-06-13 23:22 English 7.5 KB
2025-05-22 13:15
8-K
English 66.7 KB
2025-05-19 22:10 English 7.4 KB
2025-05-19 22:10 English 7.4 KB

Automate Your Workflow. Get a real-time feed of all DELCATH SYSTEMS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DELCATH SYSTEMS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DELCATH SYSTEMS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CELADON PHARMACEUTICALS PLC Logo
Researches, cultivates, and manufactures cannabinoid-based medicines for chronic pain.
United Kingdom
CEL
Celemics, Inc. Logo
Develops NGS target enrichment solutions for research and clinical applications.
South Korea
331920
Develops radiopharmaceuticals and radioligand therapies for oncology.
South Korea
308430
CELL BIOTECH CO ., LTD Logo
Develops and manufactures probiotic solutions using patented dual-coating technology.
South Korea
049960
Celldex Therapeutics, Inc. Logo
Develops antibody-based immunotherapies for severe inflammatory and allergic diseases.
United States of America
CLDX
Cellectar Biosciences, Inc. Logo
Clinical-stage biopharma developing targeted cancer treatments via a PDC platform.
United States of America
CLRB
Cellectis Logo
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
France
ALCLS
Cellid Co., Ltd. Logo
Develops immunotherapeutic vaccines for cancer and infectious diseases.
South Korea
299660
Cellromax Science Co., Ltd. Logo
Researches and develops health foods, derma-cosmetics, and OTC pharmaceuticals.
South Korea
471820
CellSeed Inc. Logo
Develops and commercializes cell sheet engineering for regenerative medicine.
Japan
7776

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.